Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.

Autor: Clarke WA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: wclarke@jhmi.edu., Chatelut E; Université de Toulouse, Inserm, Institut Claudius-Regaud, Toulouse, France., Fotoohi AK; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, 141 86, Sweden., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA., Martin JH; Centre for Drug Repurposing and Medicines Research, University of Newcastle. Level 3, Hunter Medical Research Institute, New Lambton Heights, 2305, New South Wales, Australia. Electronic address: https://twitter.com/jenhelenmar., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Salamone SJ; Saladax Biomedical Inc., Bethlehem, PA, USA.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Nov; Vol. 157, pp. 428-440. Date of Electronic Publication: 2021 Sep 28.
DOI: 10.1016/j.ejca.2021.08.033
Abstrakt: Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.
Competing Interests: Conflict of interest statement W.A.C., E.C., A.K.F. and J.H.M. have no declared conflicts of interest in relation to this work. RJHM has no conflicts of interest in relation to this work. However, his institution has received research funding for investigator-initiated research from Astellas, Bayer, Boehringer Ingelheim, Cristal Therapeutics, Novartis, PamGene, Pfizer, Roche, Sanofi and Servier. R.A.L. has acted as a consultant or advisor to Amgen, Ariad/Takeda, Astellas, Celgene/Bristol Myers Squibb, CVS/Caremark, Epizyme, MorphoSys and Novartis and has received clinical research support to his institution from Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven/Gilead, Novartis and Rafael Pharmaceuticals and royalties from UpToDate. S.J.S. is the founder and CEO of Saladax Biomedical, Inc.
(Copyright © 2021. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: